The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
The U.S. Food and Drug Administration (FDA) is considering removing the tirzepatide medications Mounjaro (for diabetes) and Zepbound (for obesity) from its drug shortage list. If that happens ...
If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...